These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 39002266)
41. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis. Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243 [TBL] [Abstract][Full Text] [Related]
42. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z Front Immunol; 2021; 12():690056. PubMed ID: 34335594 [TBL] [Abstract][Full Text] [Related]
43. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer. Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647 [TBL] [Abstract][Full Text] [Related]
44. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Chen Q; Wang J; Zhang Q; Zhang J; Lou Y; Yang J; Chen Y; Wei T; Zhang J; Fu Q; Ye M; Zhang X; Dang X; Liang T; Bai X Br J Cancer; 2019 Oct; 121(9):786-795. PubMed ID: 31588122 [TBL] [Abstract][Full Text] [Related]
45. Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity. Zhou A; Butt O; Ansstas M; Mauer E; Khaddour K; Ansstas G J Natl Compr Canc Netw; 2023 Jul; 21(7):688-693.e3. PubMed ID: 37433433 [TBL] [Abstract][Full Text] [Related]
46. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway. Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515 [TBL] [Abstract][Full Text] [Related]
47. Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma. Zhang J; Sun H; Liu S; Huang W; Gu J; Zhao Z; Qin H; Luo L; Yang J; Fang Y; Ge J; Ni B; Wang H Aging (Albany NY); 2020 Nov; 12(22):23217-23232. PubMed ID: 33221741 [TBL] [Abstract][Full Text] [Related]
48. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer. Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087 [TBL] [Abstract][Full Text] [Related]
49. Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. Li W; Gao L; Yi X; Shi S; Huang J; Shi L; Zhou X; Wu L; Ying J Genomics Proteomics Bioinformatics; 2023 Oct; 21(5):962-975. PubMed ID: 36791952 [TBL] [Abstract][Full Text] [Related]
50. Targeting both tumour-associated CXCR2 Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437 [TBL] [Abstract][Full Text] [Related]
51. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401 [TBL] [Abstract][Full Text] [Related]
52. Global targetome analysis reveals critical role of miR-29a in pancreatic stellate cell mediated regulation of PDAC tumor microenvironment. Dey S; Liu S; Factora TD; Taleb S; Riverahernandez P; Udari L; Zhong X; Wan J; Kota J BMC Cancer; 2020 Jul; 20(1):651. PubMed ID: 32660466 [TBL] [Abstract][Full Text] [Related]
54. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Casolino R; Paiella S; Azzolina D; Beer PA; Corbo V; Lorenzoni G; Gregori D; Golan T; Braconi C; Froeling FEM; Milella M; Scarpa A; Pea A; Malleo G; Salvia R; Bassi C; Chang DK; Biankin AV J Clin Oncol; 2021 Aug; 39(23):2617-2631. PubMed ID: 34197182 [TBL] [Abstract][Full Text] [Related]
55. An Immunological Glance on Pancreatic Ductal Adenocarcinoma. Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303 [TBL] [Abstract][Full Text] [Related]
56. Targeting the dynamic transcriptional landscape of Treg subpopulations in pancreatic ductal adenocarcinoma: Insights from single-cell RNA sequencing analysis with a focus on CTLA4 and TIGIT. Miraki Feriz A; Khosrojerdi A; Erfanian N; Azarkar S; Sajjadi SM; Shojaei MJ; Vaferi MJ; Safarpour H; Racanelli V Immunobiology; 2024 Jul; 229(4):152822. PubMed ID: 38852289 [TBL] [Abstract][Full Text] [Related]
57. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Yang D; Sun X; Moniruzzaman R; Wang H; Citu C; Zhao Z; Wistuba II; Wang H; Maitra A; Chen Y Gastroenterology; 2024 Jul; 167(2):298-314. PubMed ID: 38467382 [TBL] [Abstract][Full Text] [Related]